You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE, AMPLIFIED PROBE |
||
Geisinger Epic Procedure Code: LAB3915
Geisinger Epic ID: 145316
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Male urethral, female endocervical and vaginal, male and female urine, throat and rectal. | |
Preferred collection container: |
||
Special notes: |
See GML GC CT Specimen Collection Guide.
See Microbiology Collection Appendix for collection instructions. Check expiration date on transport device before use.
Check expiration date on transport device before use. For specimens collected in listed collection devices/kits, follow instruction provided. For Aptima® Unisex Swab Collection Kit (preferred device), use blue-shafted swab only. For Aptima® Multitest Swab Specimen Collection Kit, use pink-shafted swab only. NOTE: The Aptima® Multitest Swab Specimen Collection Kit is the only collection kit approved for vaginal specimens. This is not the primary collection device for GML. This test cannot be added onto a urine specimen that has already been submitted to the laboratory for testing. A fresh urine collection is required. You can add on a CTA/GCA, or TVGA on a urine specimen that has either one of these tests already ordered. |
|
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
If a single urine specimen is collected and other testing is requested, the urine specimen must be transferred to an Aptima® urine collection kit before any other testing on the urine is performed. | |
Transport temperature: |
Swab Specimens: Room temperature (2-30°C is acceptable). Urine Specimens: Room temperature (2-30°C is acceptable) in Aptima® Urine Collection Kit. Room temperature (2-30°C is acceptable) collected in sterile specimen container, stable for only 24 hours | |
Specimen stability: |
Swabs: Stable for 60 days at 2-30°C Urines: In Aptima® Urine Transport, stable 30 days at 2-30°C. In sterile container, stable for 24 hours at 2-30°C. | |
Rejection criteria: |
Improperly labeled/identified specimens. Expired transport media. Collection swabs other than Aptima® supplied/approved collection swabs. More than one swab in collection device. White cleaning swab in collection device. No swab in collection device. Urine in preservatives. Urine collection tube underfilled/overfilled. Specimens stored or transported at incorrect temperature. Specimens which exceed stability limits. Frozen specimens (unless -70°C). | |
TEST DETAILS |
||
Reference interval: |
No Chlamydia trachomatis detected by transcription-mediated nucleic acid amplification. No Neisseria gonorrhoeae detected by transcription-mediated nucleic acid amplification. | |
Critical values/courtesy alerts: |
Chlamydia trachomatis detected by transcription-mediated nucleic acid amplification and/or Neisseria gonorrhoeae detected by transcription-mediated nucleic acid amplification | |
CPT code(s): |
87491 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Molecular target amplification and detection of Chlamydia trachomatis/Neisseria gonorrhoeae. | |
Methodology: |
Dual Kinetic Assay (DKA) Transcription-Mediated Amplification (TMA) |
|
Synonyms: |
GCA, CTA, GEN-PROBE, DNA PROBE, RNA PROBE, CHLAMYDIA PROBE, CT PROBE CHLAMYDIA TRACHOMATIS PROBE, AMPLIFIED CT, AMPLIFIED CHLYAMDIA TRACHOMATIS PROBE, CT CULTURE CHLAMYDIA TRACHOMATIS, CHLAMYDIA,Neisseria probe, Neisseria gonorrhoeae probe GC probe, Amplified GC, Amplified Neisseria gonorrhoeae GC culture, Neisseria gonorrhoeae, gonococcus Probe Gonorrhoeae probe
|
|
Clinical significance: |
Chlamydia trachomatis (CT) is a leading cause of sexually transmitted disease in the U.S. A significant portion of patients with positive CT test results are asymptomatic. Neisseria gonorrhoeae is the causative agent of gonorrhea, a sexually transmitted disease. | |
Doctoral Director(s:) |
Donna Wolk PhD, D(ABMM) Julie Hirschhorn, PhD, HCLD(ABB) |
|
| Review Date: | 12/31/2022 | |